Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208393
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Marcé, Sílvia | - |
dc.contributor.author | Méndez, Aleix | - |
dc.contributor.author | Xicoy, Blanca | - |
dc.contributor.author | Estrada, Natalia | - |
dc.contributor.author | Cabezón, Marta | - |
dc.contributor.author | Sturla, Antonella Luciana | - |
dc.contributor.author | Ratia García, Miriam | - |
dc.contributor.author | Angona, Anna | - |
dc.contributor.author | Amat, Paula | - |
dc.contributor.author | Escribano Serrat, Silvia | - |
dc.contributor.author | Scalzulli, Emilia | - |
dc.contributor.author | Morgades, Mireia | - |
dc.contributor.author | Senín, Alicia | - |
dc.contributor.author | Hernández Boluda, Juan Carlos | - |
dc.contributor.author | Ferrer Marín, Francisca | - |
dc.contributor.author | Anguita, Eduardo | - |
dc.contributor.author | Cortés, Montserrat | - |
dc.contributor.author | Plensa, Esther | - |
dc.contributor.author | Breccia, Massimo | - |
dc.contributor.author | García Gutierrez, Valentín | - |
dc.contributor.author | Zamora, Lurdes | - |
dc.date.accessioned | 2024-03-05T12:34:56Z | - |
dc.date.available | 2024-03-05T12:34:56Z | - |
dc.date.issued | 2024-01-29 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/208393 | - |
dc.description.abstract | e13a2 and e14a2 are the most frequent transcript types of the BCR::ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinue TKI treatment and remain in the so-called treatment-free remission (TFR) phase, but biological factors associated with these goals are not well established. This study aimed to determine the effect of transcript type on TFR in patients receiving frontline treatment with imatinib (IM) or second-generation TKI (2G-TKI). Patients treated at least 119 months with IM presented less post-discontinuation relapse than those that discontinued IM before 119 months (p = 0.005). In addition, cases with the e14a2 transcript type treated at least 119 months with IM presented a better TFR (p = 0.024). On the other hand, the type of transcript did not affect the cytogenetic or molecular response in 2G-TKI treated patients; however, the use of 2G-TKI may be associated with higher and earlier DMR in patients with the e14a2 transcript. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm13030779 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2024, vol. 13, num. 3, p. 779 | - |
dc.relation.uri | https://doi.org/10.3390/jcm13030779 | - |
dc.rights | cc by (c) Marcé, Sílvia et al., 2024 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Leucèmia mieloide | - |
dc.subject.classification | Inhibidors enzimàtics | - |
dc.subject.other | Myeloid leukemia | - |
dc.subject.other | Enzyme inhibitors | - |
dc.title | E14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2024-02-26T12:50:43Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 38337473 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-13-00779-v2.pdf | 2.19 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License